Brian Powl serves as Chief Commercial Officer at Kura Oncology Inc., a clinical-stage biopharmaceutical company developing precision medicines for the treatment of cancer. With over 25 years of experience in the biotechnology and pharmaceutical industries, Powl has built a distinguished career focused on oncology commercial strategy, product launches, and market access. He joined Kura in 2021 to lead the company's commercial efforts as it advances its pipeline toward commercialization, including the investigational menin inhibitor ziftomenib for NPM1-mutant acute myeloid leukemia. Prior to Kura, Powl held senior leadership roles at Seagen Inc. (now part of Pfizer), where he was Senior Vice President of U.S. Commercial Oncology, overseeing the launch and growth of key antibody-drug conjugates like ADCETRIS and TIVDAK, driving significant revenue growth and market expansion. His earlier career included progressive positions at Genentech (a Roche company), Amgen, and Gilead Sciences, where he spearheaded commercial operations for blockbuster oncology therapies such as Avastin, Tarceva, and Tecentriq, consistently achieving double-digit market share gains and forging strategic partnerships with key stakeholders. At Kura Oncology, Powl is instrumental in shaping the commercial infrastructure to support near-term regulatory milestones and potential product launches. His expertise in rare disease and precision oncology positions the company to navigate complex reimbursement landscapes and build robust go-to-market strategies, leveraging his track record of transforming innovative therapies into commercial successes.